Rapid Capture of Cancer Extracellular Vesicles by Lipid Patch Microarrays

© 2021 The Authors. Advanced Materials published by Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 33(2021), 35 vom: 04. Sept., Seite e2008493
1. Verfasser: Liu, Hui-Yu (VerfasserIn)
Weitere Verfasser: Kumar, Ravi, Zhong, Chunting, Gorji, Saleh, Paniushkina, Liliia, Masood, Ramsha, Wittel, Uwe A, Fuchs, Harald, Nazarenko, Irina, Hirtz, Michael
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article breast cancer dip-pen nanolithography extracellular vesicles scanning probe lithography supported lipid bilayers Lipids Biomarkers, Tumor
Beschreibung
Zusammenfassung:© 2021 The Authors. Advanced Materials published by Wiley-VCH GmbH.
Extracellular vesicles (EVs) contain various bioactive molecules such as DNA, RNA, and proteins, and play a key role in the regulation of cancer progression. Furthermore, cancer-associated EVs carry specific biomarkers and can be used in liquid biopsy for cancer detection. However, it is still technically challenging and time consuming to detect or isolate cancer-associated EVs from complex biofluids (e.g., blood). Here, a novel EV-capture strategy based on dip-pen nanolithography generated microarrays of supported lipid membranes is presented. These arrays carry specific antibodies recognizing EV- and cancer-specific surface biomarkers, enabling highly selective and efficient capture. Importantly, it is shown that the nucleic acid cargo of captured EVs is retained on the lipid array, providing the potential for downstream analysis. Finally, the feasibility of EV capture from patient sera is demonstrated. The demonstrated platform offers rapid capture, high specificity, and sensitivity, with only a small need in analyte volume and without additional purification steps. The platform is applied in context of cancer-associated EVs, but it can easily be adapted to other diagnostic EV targets by use of corresponding antibodies
Beschreibung:Date Completed 24.07.2024
Date Revised 24.07.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202008493